FDA reviews homeopathic product regulation
16 Jun 2015
A public hearing on 20-21 April sought to obtain information and comments from stakeholders about the current use of homeopathic products in the US and their regulatory framework (see ECHAMP News item 27 March). Transcripts, recordings and presentations of this meeting are now available on the US Federal Drug Administration’s website.
FDA will continue to accept written comments from all interested parties, including consumers, patients, caregivers, health care professionals, patient groups, and industry. It is seeking input on a number of specific questions, but welcomes any other pertinent information participants would like to share. The closing date for comments is 22 June.